




# Testing Taskforce: New California COVID-19 cases, hospitalizations and deaths



### 14 day average Hospitalizations



### 7 day Average Deaths



Average test positivity past 7 days 6.5%, no change from last week

Cases remain at relatively low levels

14 day average hospitalizations have plateaued but are still 1.5x the low in October

7 day average deaths remain at low levels.

- **Turnaround Time (for the week starting 02/19)**
- **92%** of PCR tests TAT < 1 day (no change from the previous week)
- **97%** of tests TAT < 2 days (no change from the previous week)
- *as of 03/06 -- Source: CalREDIE*


Mar 2 2023 with data as of Feb 28, 2023.

<https://covid19.ca.gov/state-dashboard/>

# Daily new confirmed COVID-19 cases per million people

7-day rolling average. Due to limited testing, the number of confirmed cases is lower than the true number of infections.

Our World  
in Data




COVID-19 cases are falling in many countries around the world. In Japan, Hong Kong they are falling from a large peak. In the US cases are staying steady and relatively low. In Europe, cases remain at low levels except for in Austria where there was a rise in cases.

# Daily new confirmed COVID-19 deaths per million people

7-day rolling average. Due to varying protocols and challenges in the attribution of the cause of death, the number of confirmed deaths may not accurately represent the true number of deaths caused by COVID-19.


LINEAR LOG



# Variant Update: CDC Nowcast Estimate

Weighted and Nowcast Estimates in United States for Weeks of 11/27/2022 – 3/4/2023

Nowcast Estimates in United States for 2/26/2023 – 3/4/2023




USA					
WHO label	Lineage #	US Class	%Total	95%PI	
Omicron	XBB.1.5	VOC	89.6%	85.6-92.6%	+4.2%
	BQ.1.1	VOC	6.7%	4.7-9.4%	-2.6%
	BQ.1	VOC	1.6%	1.1-2.3%	-0.9%
	CH.1.1	VOC	0.8%	0.5-1.1%	-0.1%
	XBB	VOC	0.7%	0.5-1.0%	-0.4%
	BN.1	VOC	0.2%	0.2-0.4%	-0.2%
	BA.5	VOC	0.1%	0.1-0.1%	-0.1%
	BA.2	VOC	0.1%	0.0-0.5%	0.0%
	BF.7	VOC	0.1%	0.0-0.1%	0.0%
	BA.5.2.6	VOC	0.0%	0.0-0.0%	
	BF.11	VOC	0.0%	0.0-0.0%	
	BA.2.75	VOC	0.0%	0.0-0.0%	
	BA.2.75.2	VOC	0.0%	0.0-0.0%	
	BA.4.6	VOC	0.0%	0.0-0.0%	
	B.1.1.529	VOC	0.0%	0.0-0.0%	
	BA.2.12.1	VOC	0.0%	0.0-0.0%	
	BA.4	VOC	0.0%	0.0-0.0%	
	BA.1.1	VOC	0.0%	0.0-0.0%	
Delta	B.1.617.2	VBM	0.0%	0.0-0.0%	
Other	Other*		0.1%	0.0-0.1%	

- XBB.1.5 continues to increase
- All other lineages decreasing or unchanged in prevalence

# XBB.1.5

- Fusion of BA.2.10.1.1 and BA.2.75.3.1.1.1
- Immune evasive, evades monoclonal antibodies
- Paxlovid still works
- Lineage has the greatest increase in growth in the US
- Highest number of cases in New York and East Coast 98.7% vs 86.3% for California
- Not seeing a rise in hospitalizations or cases with increasing XBB.1.5 prevalence
- Beginning to see branching from XBB.1.5


Nowcast Estimates in for 2/26/2023 – 3/4/2023 by HHS Region



# Paxlovid Resistance Currently Not Seen

- Currently we are **NOT** seeing signs of mutations in SARS-CoV-2 likely to impact the effectiveness of Paxlovid
- We are monitoring the genomic sequencing data for known Paxlovid resistance mutations

**Figure 1. Percentage of Influenza Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date**



**Figure 13. Percentage of RSV Detections at Clinical Sentinel Laboratories, 2017–2023 Season to Date**

